Intravenous zoledronate (Reclast) administered once every 5 years reduced the incidence of morphometric vertebral fractures in early postmenopausal women, a randomized trial showed. Over 10 years of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Women who went 5 years between zoledronate infusions had ...

Following an infusion of zoledronate acid in low-risk postmenopausal women, fracture risk reduction emerged only 5-10 years later in a placebo-controlled trial. By year 10, those who received a single ...

Please provide your email address to receive an email when new articles are posted on . According to results of this 2-year level 1 study, zoledronate does not prevent femoral head collapse in ...

MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

June 7, 2011 (Boston, Massachusetts) — Lower doses than are currently prescribed of the bisphosphonate zoledronate may be enough to increase bone density and reduce bone resorption in postmenopausal ...

Background Zoledronate prevents fractures in older women when administered every 12 to 18 months, but its effects on bone density and bone turnover persist beyond 5 years. Whether infrequent ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...

Credit: Shutterstock. The researchers found that a fragility fracture occurred in 190 women in the placebo group and 122 women in the zoledronate group (hazard ratio [HR] with zoledronate, 0.63).

Editor's note: This story was updated on Oct. 23, to add conflict-of-interest disclosures for the lead author of the research study. A large study has produced strong evidence that a drug commonly ...